2.4.0.8100360 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)truefalsefalse1false USDfalsefalse$C_0001269021_20130401_20130630http://www.sec.gov/CIK0001269021duration2013-04-01T00:00:002013-06-30T00:00:00U_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$C_0001269021_20120401_20120630http://www.sec.gov/CIK0001269021duration2012-04-01T00:00:002012-06-30T00:00:00U_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$C_0001269021_20130101_20130630http://www.sec.gov/CIK0001269021duration2013-01-01T00:00:002013-06-30T00:00:00U_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$C_0001269021_20120101_20120630http://www.sec.gov/CIK0001269021duration2012-01-01T00:00:002012-06-30T00:00:00U_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBiogenIdecMember_20121101_20121130http://www.sec.gov/CIK0001269021duration2012-11-01T00:00:002012-11-30T00:00:00falsefalseBiogen Idecus-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BiogenIdecMemberus-gaap_MajorCustomersAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBiogenIdecMember_20130401_20130630http://www.sec.gov/CIK0001269021duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseBiogen Idecus-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BiogenIdecMemberus-gaap_MajorCustomersAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBiogenIdecMember_20120401_20120630http://www.sec.gov/CIK0001269021duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseBiogen Idecus-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BiogenIdecMemberus-gaap_MajorCustomersAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBiogenIdecMember_20130101_20130630http://www.sec.gov/CIK0001269021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseBiogen Idecus-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BiogenIdecMemberus-gaap_MajorCustomersAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBiogenIdecMember_20120101_20120630http://www.sec.gov/CIK0001269021duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseBiogen Idecus-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BiogenIdecMemberus-gaap_MajorCustomersAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBristolMyersSquibbCompanyAndPfizerIncMember_20130930http://www.sec.gov/CIK0001269021instant2013-09-30T00:00:000001-01-01T00:00:00falsefalseBristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BristolMyersSquibbCompanyAndPfizerIncMemberus-gaap_MajorCustomersAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBristolMyersSquibbCompanyAndPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130401_20130630http://www.sec.gov/CIK0001269021duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseBristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BristolMyersSquibbCompanyAndPfizerIncMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseCollaborative Arrangementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CollaborativeArrangementMemberus-gaap_TypeOfArrangementAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBristolMyersSquibbCompanyAndPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20120401_20120630http://www.sec.gov/CIK0001269021duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseBristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BristolMyersSquibbCompanyAndPfizerIncMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseCollaborative Arrangementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CollaborativeArrangementMemberus-gaap_TypeOfArrangementAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$13false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBristolMyersSquibbCompanyAndPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130101_20130630http://www.sec.gov/CIK0001269021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseBristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BristolMyersSquibbCompanyAndPfizerIncMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseCollaborative Arrangementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CollaborativeArrangementMemberus-gaap_TypeOfArrangementAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$14false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBristolMyersSquibbCompanyAndPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20120101_20120630http://www.sec.gov/CIK0001269021duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseBristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BristolMyersSquibbCompanyAndPfizerIncMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseCollaborative Arrangementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CollaborativeArrangementMemberus-gaap_TypeOfArrangementAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$15false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaLeePharmaceuticalHkLtdMember_20130101_20130131http://www.sec.gov/CIK0001269021duration2013-01-01T00:00:002013-01-31T00:00:00falsefalseLee's Pharmaceutical (HK) Ltd ("Lee's")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_LeePharmaceuticalHkLtdMemberus-gaap_MajorCustomersAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$16false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaLeePharmaceuticalHkLtdMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130401_20130630http://www.sec.gov/CIK0001269021duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseLee's Pharmaceutical (HK) Ltd ("Lee's")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_LeePharmaceuticalHkLtdMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseCollaborative Arrangementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CollaborativeArrangementMemberus-gaap_TypeOfArrangementAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$17false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaLeePharmaceuticalHkLtdMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130101_20130630http://www.sec.gov/CIK0001269021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseLee's Pharmaceutical (HK) Ltd ("Lee's")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_LeePharmaceuticalHkLtdMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseCollaborative Arrangementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CollaborativeArrangementMemberus-gaap_TypeOfArrangementAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$18false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaAciexTherapeuticsIncMember_20130401_20130630http://www.sec.gov/CIK0001269021duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseAciex Therapeutics, Inc. (Aciex)us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_AciexTherapeuticsIncMemberus-gaap_MajorCustomersAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$19false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaAciexTherapeuticsIncMember_20130101_20130630http://www.sec.gov/CIK0001269021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseAciex Therapeutics, Inc. (Aciex)us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_AciexTherapeuticsIncMemberus-gaap_MajorCustomersAxisexplicitMemberU_pureStandardhttp://www.xbrl.org/2003/instancepure0U_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$20false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBayerPharmaAgMember_20130102_20130201http://www.sec.gov/CIK0001269021duration2013-01-02T00:00:002013-02-01T00:00:00falsefalseBayer Pharma AGus-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BayerPharmaAgMemberus-gaap_MajorCustomersAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$21false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaJanssenPharmaceuticalsIncrMember_20130102_20130201http://www.sec.gov/CIK0001269021duration2013-01-02T00:00:002013-02-01T00:00:00falsefalseJanssen Pharmaceuticals, Inc.us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_JanssenPharmaceuticalsIncrMemberus-gaap_MajorCustomersAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$22false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBayerPharmaAgAndJanssenPharmaceuticalsIncrMember_20130102_20130201http://www.sec.gov/CIK0001269021duration2013-01-02T00:00:002013-02-01T00:00:00falsefalseBayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BayerPharmaAgAndJanssenPharmaceuticalsIncrMemberus-gaap_MajorCustomersAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$23false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBayerPharmaAgAndJanssenPharmaceuticalsIncrMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130401_20130630http://www.sec.gov/CIK0001269021duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseBayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BayerPharmaAgAndJanssenPharmaceuticalsIncrMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseCollaborative Arrangementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CollaborativeArrangementMemberus-gaap_TypeOfArrangementAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$24false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBayerPharmaAgAndJanssenPharmaceuticalsIncrMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20120401_20120630http://www.sec.gov/CIK0001269021duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseBayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BayerPharmaAgAndJanssenPharmaceuticalsIncrMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseCollaborative Arrangementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CollaborativeArrangementMemberus-gaap_TypeOfArrangementAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$25false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBayerPharmaAgAndJanssenPharmaceuticalsIncrMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130101_20130630http://www.sec.gov/CIK0001269021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseBayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BayerPharmaAgAndJanssenPharmaceuticalsIncrMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseCollaborative Arrangementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CollaborativeArrangementMemberus-gaap_TypeOfArrangementAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$26false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaBayerPharmaAgAndJanssenPharmaceuticalsIncrMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20120101_20120630http://www.sec.gov/CIK0001269021duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseBayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_BayerPharmaAgAndJanssenPharmaceuticalsIncrMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseCollaborative Arrangementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CollaborativeArrangementMemberus-gaap_TypeOfArrangementAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$27false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaDaiichiSankyoIncMember_20130101_20130630http://www.sec.gov/CIK0001269021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseDaiichi Sankyo, Inc. ("Daiichi")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_DaiichiSankyoIncMemberus-gaap_MajorCustomersAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$28false USDtruefalse$C_0001269021_us-gaapMajorCustomersAxis_ptlaDaiichiSankyoIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130101_20130630http://www.sec.gov/CIK0001269021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseDaiichi Sankyo, Inc. ("Daiichi")us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldiptla_DaiichiSankyoIncMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseCollaborative Arrangementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CollaborativeArrangementMemberus-gaap_TypeOfArrangementAxisexplicitMemberU_iso4217USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$29false truefalseC_0001269021_deiLegalEntityAxis_us-gaapParentCompanyMember_20130101_20130630http://www.sec.gov/CIK0001269021duration2013-01-01T00:00:002013-06-30T00:00:00falsefalsePORTOLA PHARMACEUTICALS INCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ParentCompanyMemberdei_LegalEntityAxisexplicitMemberU_pureStandardhttp://www.xbrl.org/2003/instancepure01true 3us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Research And Development Arrangement Contract To Perform For Others [Line Items]2false 4ptla_LicenseFeeReceivableUponOccurrenceOfCertainDevelopmentAndRegulatoryEventsptla_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse370000000370000000USD$falsetruefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryLicense fee receivable upon occurrence of certain development and regulatory events.No definition available.false2License fee receivable upon occurrence of certain development and regulatory events3false 4ptla_NoticePeriodForAgreementTerminationptla_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00120 daysfalsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse0060 daysfalsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaNotice Period For Agreement TerminationNo definition available.false0Notice period for agreement termination4false 4ptla_ReductionToResearchAndDevelopmentExpenseptla_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse164000164000falsefalsefalse7truefalsefalse21000002100000falsefalsefalse8truefalsefalse494000494000falsefalsefalse9truefalsefalse48000004800000falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryReduction To Research And Development ExpenseNo definition available.false2Reduction in research and development expense5false 4us-gaap_DeferredRevenueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse60000006000000falsefalsefalse11truefalsefalse900000900000falsefalsefalse12falsefalsefalse00falsefalsefalse13truefalsefalse900000900000falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16truefalsefalse648000648000falsefalsefalse17truefalsefalse648000648000falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23truefalsefalse26000002600000falsefalsefalse24falsefalsefalse00falsefalsefalse25truefalsefalse26000002600000falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28truefalsefalse29000002900000falsefalsefalse29falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A false2Deferred revenue6false 4us-gaap_DeferredRevenueRevenueRecognizedus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11truefalsefalse11000001100000falsefalsefalse12falsefalsefalse00  falsefalsefalse13truefalsefalse31000003100000falsefalsefalse14falsefalsefalse00  falsefalsefalse15falsefalsefalse00falsefalsefalse16truefalsefalse5200052000falsefalsefalse17truefalsefalse5200052000falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23truefalsefalse13000001300000falsefalsefalse24falsefalsefalse00  falsefalsefalse25truefalsefalse24000002400000falsefalsefalse26falsefalsefalse00  falsefalsefalse27falsefalsefalse00falsefalsefalse28truefalsefalse125000125000falsefalsefalse29falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A false2Collaboration revenue recognized7false 4us-gaap_ProceedsFromLicenseFeesReceivedus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15truefalsefalse700000700000falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20truefalsefalse25000002500000falsefalsefalse21truefalsefalse25000002500000falsefalsefalse22truefalsefalse50000005000000falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCash received from licensees for license fees during the current period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 27 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Upfront and non-refundable fee8false 4ptla_CostSharingPercentageptla_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10falsetruefalse00falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalse14falsetruefalse00falsefalsefalse15falsetruefalse00falsefalsefalse16falsetruefalse00falsefalsefalse17falsetruefalse00falsefalsefalse18falsetruefalse00falsefalsefalse19truetruefalse0.600.60falsefalsefalse20falsetruefalse00falsefalsefalse21falsetruefalse00falsefalsefalse22falsetruefalse00falsefalsefalse23falsetruefalse00falsefalsefalse24falsetruefalse00falsefalsefalse25falsetruefalse00falsefalsefalse26falsetruefalse00falsefalsefalse27falsetruefalse00falsefalsefalse28falsetruefalse00falsefalsefalse29truetruefalse0.400.40falsefalsefalsenum:percentItemTypepureCost Sharing PercentageNo definition available.false0Development costs, percent9false 4us-gaap_ResearchAndDevelopmentExpenseus-gaap_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:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph g -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11, 12 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Research and development10false 4ptla_CollaborativeArrangementAdditionalUpFrontPaymentToBeReceivedptla_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20truefalsefalse250000250000falsefalsefalse21truefalsefalse250000250000falsefalsefalse22truefalsefalse500000500000falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCollaborative Arrangement Additional UpFront Payment To Be ReceivedNo definition available.false2Additional upfront and non-refundable fee11false 4ptla_CollaborativeArrangementUpFrontPaymentToBeReceivedptla_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27truefalsefalse60000006000000falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCollaborative ​arrangement​ ​up front ​payment ​to be ​received.No definition available.false2Collaborative arrangement up front payment to be received12false 4ptla_UpfrontFeeSubjectToRefundptla_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27truefalsefalse30000003000000falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryUpfront fee subject to refund.No definition available.false2Upfront fee subject to refund13false 4ptla_ContingentConsiderationOfCollaborationArrangementptla_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28truefalsefalse30000003000000falsefalsefalse29falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryContingent consideration of collaboration arrangement.No definition available.false2Contingent consideration of collaboration arrangement14false 4ptla_NonContingentConsiderationBeingRecognizedAsRevenueOverEstimatedPeriodOfPerformanceptla_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28truefalsefalse30000003000000USD$falsetruefalse29falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryNon contingent consideration being recognized as revenue over estimated period of performance.No definition available.false2Non-contingent consideration being recognized as revenue over estimated period of performancefalseCollaboration and License Agreements - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.portola.com/20130630/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail2914